Author/Authors :
Dorchin، M نويسنده Radiation Oncologist, Oncology Department, Dezfol University of Medical Sciences. Dezfol. Iran , , Masoumi، R نويسنده Health Policy Research Center, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran , , Soleiman، S نويسنده HematoOncologist, Oncology department, Al-Bairouni University Hospital, Medical faculty, Damascus University, Damascus, Syria. , , Manashi، M نويسنده HematoOncologist, Oncology department, Al-Bairouni University Hospital, Medical faculty, Damascus University, Damascus, Syria. ,
Abstract :
Back ground:
Vincristine (VCR), is a chemotherapy drug, useful in the treatment of leukemia, lymphoma and solid tumor and it is a potent neurotoxin and sensory neuropathy drug which a common behavioral toxicity of this drug. Neuropathy is common squeal of intensive chemotherapy protocols that contain vincristine and corticosteroids.
Materials and Methods:
This study was a retrospective and descriptive study of neuropathy during in chemotherapy program with vincristine for patients with non-Hodgkinʹs lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL). Data was analyzed by spss Version16 software.
Results:
From total of 51 cases, 23 patients had vincristine neuropathy (45%).
Patients with visceral neuropathy have shown ileus, constipation in 13 patients (25%), occasionally severe diarrhea 11 (21%), mild diarrhea 7 (13.7%) and transient diarrhea in 16 patients (31%).
Motor neuropathy were found in one patient with Bell, s palsy (1.9%) and one patient with Hoarseness. 12 patients (23.5%) had some type of complication together with sensory peripheral neuropathy.
Conclusion:
Almost half of patients with vincristin chemotherapy had neuropathy and the mean age of patients with neuropathy was 12.3 years.